News

Reschedule Meeting, Supplemental Disclosure for Transaction involving the Sale of Assets and Board Update

1 days ago Dec 20, 2024

RepliCel Life Sciences Reschedules Meeting, Provides Supplemental Disclosure for Transaction involving the Sale of Assets...

Shareholders that have questions are encouraged to contact Andrew Schutte at info@replicel.com or call (604) 248-8730

16 days ago Dec 05, 2024

Shareholders that have questions are encouraged to contact Andrew Schutte at: info@replicel.com or call (604)...

Information Circular and Form of Proxy for AGM and Special Meeting 2024 for Download

17 days ago Dec 04, 2024

RepliCel Life Sciences Inc. AGM and Special Shareholder Meeting PDFs Available for Download:RepliCel - Information...

RepliCel Files Information Circular for AGM and Special Shareholders Meeting and Encourages Shareholders to Access Meeting Materials Online

17 days ago Dec 04, 2024

RepliCel Life Sciences Files Management Information Circular for Annual General and Special Shareholders Meeting and...

Closing of Preferred Share Conversion and Settlement of Dividends

25 days ago Nov 26, 2024

RepliCel Life Sciences Announces Closing of Preferred Share Conversion and Settlement of DividendsVANCOUVER, BC –...

Notice of Meeting and Record Date Nov Dec 2024

1 month ago Nov 15, 2024

November 5, 2024 Filed via SEDAR+ To All Applicable Exchanges and Securities Administrators Subject: RepliCel...

Preferred Share Conversion

1 month ago Nov 15, 2024

RepliCel Life Sciences Announces Intention to complete Preferred Share Conversion and Settlement of DividendsVANCOUVER, BC...

RepliCel Life Sciences Announces Reinstatement of Trading & Conditional Acceptance for Proposed Transaction

2 months ago Oct 17, 2024

RepliCel Life Sciences Announces Reinstatement of Trading & Conditional Acceptance for Proposed Transaction VANCOUVER, BC, CANADA...

RepliCel Life Sciences enters into Definitive Agreements for sale of Company Assets

4 months ago Aug 28, 2024

RepliCel Life Sciences enters into Definitive Agreements for sale of Company AssetsVANCOUVER, BC, CANADA –August...

RepliCel Announces Secured Loan Agreement

8 months ago Apr 18, 2024

RepliCel Announces Secured Loan AgreementVANCOUVER, BC, CANADA –April 17, 2024 – RepliCel Life Sciences Inc....

RepliCel Signs Letter of Intention (Asset Purchase)

9 months ago Mar 18, 2024

RepliCel announces a Letter of Intent for Asset Purchase AgreementVANCOUVER, BC, CANADA –March 18, 2024...

Arbitration decision

1 years ago Oct 17, 2023

RepliCel Life Sciences Announces Arbitration Decision VANCOUVER, BC – October 16, 2023 - RepliCel Life...

RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings

1 years ago Sep 14, 2023

RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration ProceedingsVANCOUVER, BC, CANADA – September 13, 2023 –...

David Kwok is appointed Chief Financial Officer

1 years ago Aug 17, 2023

RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is...

RepliCel Adds an Additional Director, Jamie Mackay

1 years ago Aug 10, 2023

RepliCel Adds an Additional Director RepliCel Life Sciences Strengthens Its Board of Directors as focus shifts...

AGM Announced for September 22, 2023

1 years ago Aug 10, 2023

REPLICEL LIFE SCIENCES INC. Suite 900 – 570 Granville Street Vancouver, BC V6C 3P1 Telephone: (604) 248-8730 Fax:...

RepliCel Announces Closing of Non-brokered Private Placement

2 years ago Mar 14, 2023

RepliCel Announces Closing of Non-brokered Private PlacementNot for distribution to U.S. Newswire Services or for...

RepliCel Provides Corporate Update

2 years ago Nov 28, 2022

Company Focus on Transformational Milestones Vancouver, BC, Canada – 28 November 2022 - RepliCel Life Sciences Inc. (TSXV:...

RepliCel Announces Material Patent Milestones in Key Markets

2 years ago Aug 04, 2022

New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key...

DermaPreciseTM Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections

2 years ago Aug 02, 2022

Independent Testing Performed by Innovacell Demonstrates the DermaPreciseTM Control Leads to Unparalleled Post-Injection Cell Survival and...

by Type

by Topic

by month

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.